Comparative quantitative analysis of SARS- CoV-2 Spike neutralizing antibody titers following two anti COVID-19 vaccines in India
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
In COVID 19 Pandemic,first line of defence is effective vaccination program.Because of multiple platforms available for vaccine production we tested relative immunogenicity of two vaccines available in India, Covaxin® and Covishield® We performed quantitative analysis of neutralizing antibodies to SARS Cov2 spike (receptor binding domain) protein, from sera of 53 subjects who completed vaccines schedules.There was significantly higher immunogenic response with Covishield® as compared to Covaxin® and are independent of age. Studies on a large scale with long term follow up are needed to further advance the knowledge in this domain.
Article activity feed
-
-
SciScore for 10.1101/2021.08.28.21262753: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable Results Of the 53 subjects (males 30 and females 23), 28 have titers ≥ 250. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources We quantified serum IgG anti spike neutralizing antibodies directed for receptor binding domain (RBD), employing CLIA Any numeric value over and above 250 was rounded off to 250. serum IgGsuggested: Nonespike neutralizing antibodies directed for receptor binding domain (RBD), employing CLIA Any numeric value over and above 250 was rounded off to 250.suggested: NoneSoftware and Algorithms Sentences Resources For Covaxin® it was 23.7 ± 50.05 and for Covishield® it … SciScore for 10.1101/2021.08.28.21262753: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable Results Of the 53 subjects (males 30 and females 23), 28 have titers ≥ 250. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources We quantified serum IgG anti spike neutralizing antibodies directed for receptor binding domain (RBD), employing CLIA Any numeric value over and above 250 was rounded off to 250. serum IgGsuggested: Nonespike neutralizing antibodies directed for receptor binding domain (RBD), employing CLIA Any numeric value over and above 250 was rounded off to 250.suggested: NoneSoftware and Algorithms Sentences Resources For Covaxin® it was 23.7 ± 50.05 and for Covishield® it was 126 ± 149 .p value was 0.04 (p < 0.05 being statistically significant). Covaxin®suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-